How India Exports Biotin to the World

Biotin, classified under HS Code 30049099, is widely recognized as a dietary supplement in the United States. As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for biotin, indicating the absence of FDA-approved generic formulations. This suggests that biotin is primarily marketed as a dietary supplement rather than a prescription or over-the-counter drug.

Regarding import alerts, the FDA has issued Import Alert 66-66, titled "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122," published on October 22, 2024. This alert pertains to active pharmaceutical ingredients (APIs) that do not comply with specific labeling requirements. While biotin is not explicitly mentioned in this alert, it underscores the importance of adhering to FDA labeling standards for APIs imported into the U.S.

Given that 76 Indian exporters are actively involved in the biotin market, it is crucial for these entities to ensure compliance with FDA regulations to facilitate smooth entry into the U.S. market.

In the European Union and the United Kingdom, biotin is commonly marketed as a dietary supplement and is not typically subject to the stringent marketing authorization processes required for medicinal products. However, any health claims associated with biotin must comply with the European Food Safety Authority (EFSA) regulations. Manufacturers must ensure that their facilities meet the Good Manufacturing Practice (GMP) standards set forth by the European Medicines Agency (EMA) to guarantee product quality and safety.

Biotin is not included in the World Health Organization's (WHO) Model List of Essential Medicines, indicating that it is not considered essential for a basic health system. Consequently, biotin has not undergone the WHO Prequalification process. However, biotin is recognized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), which establish quality standards for its use.

In India, biotin is classified as an over-the-counter (OTC) product, allowing consumers to purchase it without a prescription. As of March 2026, biotin is not listed under the Drug Price Control Order (DPCO) by the National Pharmaceutical Pricing Authority (NPPA), meaning it is not subject to government-mandated price controls. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations.

Biotin is a naturally occurring vitamin and is not subject to patent protection. This lack of exclusivity has led to a competitive market with numerous manufacturers producing biotin supplements, resulting in a diverse range of products available to consumers.

In October 2025, the FDA updated Import Alert 66-66, emphasizing the need for accurate labeling of APIs to prevent misbranding.

In November 2025, the UK's Food Standards Agency (FSA) implemented the Genetic Technology (Precision Breeding) Regulations 2025, allowing businesses to apply for Precision Bred Organism (PBO) food and feed marketing authorizations. While this regulation primarily targets genetically modified organisms, it reflects the evolving regulatory landscape affecting dietary supplements. (food.gov.uk)

In December 2025, the European Medicines Agency (EMA) updated its guidelines on GMP compliance, reinforcing the importance of adhering to quality standards in pharmaceutical manufacturing. This update is pertinent to biotin manufacturers exporting to the EU, as compliance with GMP is mandatory for market access.

In January 2026, the WHO revised its pharmacopoeia standards, including updated monographs for vitamins such as biotin. These revisions aim to harmonize quality standards globally, impacting manufacturers and exporters of biotin supplements.

In February 2026, the Indian Ministry of Health and Family Welfare announced plans to review the classification of certain dietary supplements, including biotin, to ensure consumer safety and product efficacy. This initiative may lead to reclassification or additional regulatory requirements for biotin products in India.

India's pharmaceutical industry, including the production of Biotin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70-80% of India's API and KSM requirements are sourced from China, making the industry vulnerable to supply chain disruptions and geopolitical tensions.

Recent geopolitical events have exacerbated these vulnerabilities. In June 2025, escalating military conflicts led to the potential closure of the Strait of Hormuz, a critical chokepoint for global energy and raw material supplies. This disruption threatened to impact the availability of petrochemical feedstocks essential for API synthesis, thereby affecting pharmaceutical manufacturing processes. (pharmasource.global)

Our proprietary trade data indicates a high supplier concentration in Biotin exports from India. The top five exporters account for 87.9% of total exports, with KUSUM HEALTHCARE PRIVATE LIMITED alone holding a 76.4% share. This significant concentration poses a single-source risk, as any operational or financial issues within these key suppliers could disrupt the entire supply chain.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic API production and reduce dependency on imports. However, the effectiveness of this initiative in diversifying the supplier base for Biotin remains to be fully realized.

Geopolitical tensions have led to significant disruptions in global shipping routes. The closure of the Strait of Hormuz in early 2026 halted oil tanker movements, affecting not only energy supplies but also the transportation of pharmaceuticals and other goods. Cargo ships faced delays, and air cargo routes were constrained due to closed airspace in several Middle Eastern countries.

Additionally, instability in the Red Sea and Suez Canal, exacerbated by regional conflicts, forced shipping companies to reroute vessels around Africa's Cape of Good Hope. This detour added approximately 10 to 14 days to transit times, leading to logistical challenges and increased costs for pharmaceutical exports from India.

• Diversify Supplier Base: Encourage the development of alternative domestic suppliers for Biotin to reduce reliance on a limited number of exporters.

• Enhance Domestic API Production: Accelerate the implementation and effectiveness of the PLI scheme to strengthen domestic API manufacturing capabilities.

• Develop Alternative Shipping Routes: Explore and invest in alternative shipping routes and logistics solutions to mitigate the impact of geopolitical disruptions.

• Strengthen Inventory Management: Implement robust inventory management practices to buffer against supply chain disruptions and ensure continuity of supply.

• Monitor Geopolitical Developments: Establish a dedicated team to monitor geopolitical events and assess their potential impact on the supply chain, enabling proactive risk management.

RISK_LEVEL: HIGH